How long is it generally recommended to take Ribociclib/Ribociclib?

Ribociclib is an oral CDK4/6 inhibitor mainly used to treat patients with hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. Regarding the taking time of Riboxil, clinical practice and multiple large-scale clinical trials show that it is usually recommended to continue taking the drug until the patient develops disease progression or intolerable side effects. In other words, there is no fixed time limit for the treatment course of Riboxil, but it is adjusted according to the patient's individual disease response and tolerance.

This drug is often used in combination with endocrine therapy (such as letrozole or fulvestrant) to form a long-term maintenance treatment regimen. The dosage is usually a 28-day cycle, with 21 consecutive days of taking and then 7 days of discontinuation to reduce the risk of adverse reactions. The MONALEESA series of clinical trials (including MONALEESA-2 and MONALEESA-7) provide strong clinical evidence for the long-term use of Riboxiclib. Research data show that patients’ progression-free survival and overall survival are significantly prolonged under combined endocrine therapy, and the safety of long-term medication is good.

Nonetheless, during long-term medication, it is still necessary to regularly monitor the patient's hematological indicators such as white blood cell and platelet counts, liver function and electrocardiogram, especially pay attention to changes in QT interval to ensure timely adjustment of dosage to prevent potential serious adverse events. Each patient's specific medication time is affected by the disease progression rate, body tolerance, and side effects. Therefore, doctors will dynamically adjust the medication plan based on clinical observations and laboratory test results.

Overall, the medication strategy of Riboxil embodies the concept of modern precision treatment, emphasizing continuous, individualized and safe management, aiming to delay the progression of cancer to the greatest extent and improve patients' quality of life and life expectations. For patients and their families, understanding the dosage cycle of Riboxil requires the guidance of a doctor and close cooperation with follow-up examinations to achieve good therapeutic effects.

Reference materials:https://us.kisqali.com/